- Home
- CHRS vs MSGY Comparison
CHRS vs MSGY Comparison
Compare CHRS & MSGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- MSGY
- Stock Information
- Founded
- CHRS 2010
- MSGY 2018
- Country
- CHRS United States
- MSGY Hong Kong
- Employees
- CHRS N/A
- MSGY N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- MSGY
- Sector
- CHRS Health Care
- MSGY
- Exchange
- CHRS Nasdaq
- MSGY Nasdaq
- Market Cap
- CHRS 159.2M
- MSGY 186.3M
- IPO Year
- CHRS 2014
- MSGY 2025
- Fundamental
- Price
- CHRS $1.35
- MSGY $14.40
- Analyst Decision
- CHRS Strong Buy
- MSGY
- Analyst Count
- CHRS 4
- MSGY 0
- Target Price
- CHRS $4.51
- MSGY N/A
- AVG Volume (30 Days)
- CHRS 1.2M
- MSGY 196.2K
- Earning Date
- CHRS 11-05-2025
- MSGY 01-01-0001
- Dividend Yield
- CHRS N/A
- MSGY N/A
- EPS Growth
- CHRS N/A
- MSGY N/A
- EPS
- CHRS 1.55
- MSGY 0.10
- Revenue
- CHRS $272,209,000.00
- MSGY $23,318,482.00
- Revenue This Year
- CHRS N/A
- MSGY N/A
- Revenue Next Year
- CHRS $109.48
- MSGY N/A
- P/E Ratio
- CHRS $0.87
- MSGY $139.53
- Revenue Growth
- CHRS 52.33
- MSGY 13.04
- 52 Week Low
- CHRS $0.66
- MSGY $3.83
- 52 Week High
- CHRS $2.43
- MSGY $18.68
- Technical
- Relative Strength Index (RSI)
- CHRS 64.99
- MSGY N/A
- Support Level
- CHRS $1.23
- MSGY N/A
- Resistance Level
- CHRS $1.40
- MSGY N/A
- Average True Range (ATR)
- CHRS 0.08
- MSGY 0.00
- MACD
- CHRS -0.00
- MSGY 0.00
- Stochastic Oscillator
- CHRS 72.13
- MSGY 0.00
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About MSGY Masonglory Limited Ordinary Shares
Masonglory Ltd is a a holding company and operates through subsidiary. It is engaged in the provision of wet trades services and other ancillary services as a subcontractor in Hong Kong. As a subcontractor, It provide customers with comprehensive wet trades works solutions, which principally include plastering on floors, ceilings and walls, tile laying on internal and external walls and floors, brick laying, floor screeding, and marble works.